StreetInsider.com News Articles

Enanta Pharmaceuticals to Participate in September Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September:

Baird 2026 Global Healthcare Conference: Fireside Chat on Tuesday, September 15, 2026 at 1:25 p.m. ET
H.C. Wainwright 28th Annual Global Investment Conference: Fireside Chat on Wednesday, September 16, 2026 at 8:00 a.m. ET

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at

Enanta Pharmaceuticals to Participate in September Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

Baird 2026 Global Healthcare Conference: Fireside Chat on Tuesday, September 15, 2026 at 1:25 p.m. ET
H.C. Wainwright 28th Annual Global Investment Conference: Fireside Chat on Wednesday, September 16, 2026 at 8:00 a.m. ET

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at

Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:26:00 -0400

si-local-file:///var/storage/secattach/20260814/26925060.html

Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:26:00 -0400

si-local-file:///var/storage/secattach/20260814/26925060.html

Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26925010.html

Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26925010.html

Form 10-Q ENANTA PHARMACEUTICALS For: Jun 30

Wed, 12 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26908734.html

Form 10-Q ENANTA PHARMACEUTICALS For: Jun 30

Wed, 12 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26908734.html

Form 8-K ENANTA PHARMACEUTICALS For: Aug 10

Mon, 10 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26897778.html

Form 8-K ENANTA PHARMACEUTICALS For: Aug 10

Mon, 10 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26897778.html

Enanta Pharma (ENTA) Misses Q3 EPS by 17c

Mon, 10 Aug 2026 16:02:03 -0400

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.67), $0.17 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $14.35 million versus the consensus estimate of $17.4 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027
On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027
On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026
On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026
Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Mon, 10 Aug 2026 16:01:00 -0400

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027

On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026

On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026

Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as